Advertisement

FAT4 hypermethylation and grade dependent downregulation in gastric adenocarcinoma

  • Maryam Pilehchian Langroudi
  • Novin Nikbakhsh
  • Ali Akbar Samadani
  • Sadegh Fattahi
  • Hassan Taheri
  • Shahryar Shafaei
  • Galia Amirbozorgi
  • Reza Pilehchian Langroudi
  • Haleh Akhavan-NiakiEmail author
RESEARCH ARTICLE

Abstract

Gastric cancer is one of the major causes of death due to cancer in the world. It is a multi-factorial disease with epigenetic factors being also involved in its development. FAT4 is a tumor suppressor gene exerting an important role in cell adhesion. This study aimed at analyzing FAT4 expression and promoter methylation in gastric cancer. FAT4 expression was studied in 30 tumoral tissues and their non-tumoral counterparts using Taqman real time PCR method. Promoter methylation was assessed using bisulfite conversion method followed by sequencing. Tumor tissues showed reduced FAT4 expression (P = 0.04). FAT4 downregulation was associated with tumor grade, with higher repression at advanced grades. Significant increase of promoter methylation was observed in tumoral tissues. Reduced expression of FAT4 and increased methylation of its promoter may be one of the effective processes in turning a healthy stomach tissue into a tumor tissue.

Keywords

Gastric cancer FAT4 Gene expression Promoter methylation 

Notes

Acknowledgments

This work was supported by the Research Deputy of Babol University of Medical Sciences. Authors would like to express their gratitude to the director and staffs of Razi Pathobiology laboratory, Babol, Iran, and North Research Center of Pasteur Institute, Amol, Iran for providing necessary instruments for accomplishing some experimental parts of this study. We appreciate the helpful comments from the staff members of the said university, research center and laboratory.

Compliance with ethical standards

Conflict of interest

Authors declare no conflict of interest.

References

  1. Akhavan-Niaki H, Samadani AA (2013) DNA methylation and cancer development: molecular mechanism. Cell Biochem Biophys 67:501–513CrossRefPubMedGoogle Scholar
  2. Akhavan-Niaki H, Samadani AA (2014) Molecular insight in gastric cancer induction: an overview of cancer stemness genes. Cell Biochem Biophys 68:463–473CrossRefPubMedGoogle Scholar
  3. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16:6–21CrossRefPubMedGoogle Scholar
  4. Cai J, Feng D, Hu L, Chen H, Yang G, Cai Q, Gao C, Wei D (2015) FAT4 functions as a tumour suppressor in gastric cancer by modulating Wnt/β-catenin signalling. Br J Cancer 113:1720–1729CrossRefPubMedPubMedCentralGoogle Scholar
  5. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–463CrossRefPubMedGoogle Scholar
  6. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143–153CrossRefPubMedGoogle Scholar
  7. Fukushige S, Horii A (2013) DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med 229:173–185CrossRefPubMedGoogle Scholar
  8. Galm O, Esteller M (2004) Beyond genetics--the emerging role of epigenetic changes in hematopoietic malignancies. Int J Hematol 80:120–127CrossRefPubMedGoogle Scholar
  9. Herman JG (1999) Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 9:359–367CrossRefPubMedGoogle Scholar
  10. Ito T, Taniguchi H, Fukagai K, Okamuro S, Kobayashi A (2015) Inhibitory mechanism of FAT4 gene expression in response to actin dynamics during Src-induced carcinogenesis. PLoS One 10:e0118336CrossRefPubMedPubMedCentralGoogle Scholar
  11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90CrossRefPubMedGoogle Scholar
  12. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428CrossRefPubMedGoogle Scholar
  13. Jung HY, Cho H, MH O, Lee JH, Lee HJ, Jang SH, Lee MS (2015) Loss of FAT atypical cadherin 4 expression is associated with high pathologic T stage in radically resected gastric cancer. J Gastric Cancer 15:39–45CrossRefPubMedPubMedCentralGoogle Scholar
  14. Katoh M (2012) Function and cancer genomics of FAT family genes (review. Int J Oncol 41:1913–1918PubMedPubMedCentralGoogle Scholar
  15. Kumaki Y, Oda M, Okano M (2008) QUMA: quantification tool for methylation analysis. Nucleic Acids Res 36:W170–W175CrossRefPubMedPubMedCentralGoogle Scholar
  16. Lee YS, Cho YS, Lee GK, Lee S, Kim YW, Jho S, Kim HM, Hong SH, Hwang JA, Kim SY, Hong D, Choi IJ, Kim BC, Kim BC, Kim CH, Choi H, Kim Y, Kim KW, Kong G, Kim HL, Bhak J, Lee SH, Lee JS (2014) Genomic profile analysis of diffuse-type gastric cancers. Genome biol 15:R55CrossRefPubMedPubMedCentralGoogle Scholar
  17. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25:402–408CrossRefPubMedGoogle Scholar
  18. Malekzadeh R, Derakhshan MH, Malekzadeh Z (2009) Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med 12:576–583PubMedGoogle Scholar
  19. Mani S, Herceg Z (2010) DNA demethylating agents and epigenetic therapy of cancer. Adv Genet 70:327–340PubMedGoogle Scholar
  20. Marin JJ, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales JM, Macias RI (2016) Mechanisms of resistance to chemotherapy in gastric cancer. Anti Cancer Agents Med Chem 16:318–334CrossRefGoogle Scholar
  21. Mizuno H, Kitada K, Nakai K, Sarai A (2009) PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genet 2:18Google Scholar
  22. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. (2012) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44:133–139CrossRefGoogle Scholar
  23. Park JH, Park J, Choi JK, Lyu J, Bae MG, Lee YG, Bae JB, Park DY, Yang HK, Kim TY, Kim YJ (2011) Identification of DNA methylation changes associated with human gastric cancer. BMC Med Genet 4:82Google Scholar
  24. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36CrossRefPubMedPubMedCentralGoogle Scholar
  25. Qi C, Zhu YT, Hu L, Zhu Y-J (2009) Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int J Cancer 124:793–798CrossRefPubMedPubMedCentralGoogle Scholar
  26. Qu Y, Dang S, Hou P (2013) Gene methylation in gastric cancer. Clin Chim Acta 424:53–65CrossRefPubMedGoogle Scholar
  27. Rauch TA, Wang Z, Wu X, Kernstine KH, Riggs AD, Pfeifer GP (2012) DNA methylation biomarkers for lung cancer. Tumour Biol 33:287–296CrossRefPubMedGoogle Scholar
  28. Samadani A, Akhavan-Niaki H (2015) Interaction of sonic hedgehog (SHH) pathway with cancer stem cell genes in gastric cancer. Med Oncol 32:1–7CrossRefGoogle Scholar
  29. Samadani AA, Nikbakhsh N, Fattahi S, Pourbagher R, Aghajanpour Mir SM, Mousavi Kani N, Abedian Z, Akhavan-Niaki H (2015) RNA extraction from animal and Human’s cancerous tissues: does tissue matter? Int J Mol Cell Med 4:54–59PubMedPubMedCentralGoogle Scholar
  30. Sebova K, Fridrichova I (2010) Epigenetic tools in potential anticancer therapy. Anti-cancer. Drugs 21:565–577Google Scholar
  31. World Health Organization (2014) (February 2014. Retrieved 10 June 2014) Cancer Fact sheet N°297Available from: http://www.who.int/mediacentre/factsheets/fs297/en/.
  32. Worm J, Guldberg P (2002) DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. J Oral Pathol Med 31:443–449CrossRefPubMedGoogle Scholar
  33. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5:37–50CrossRefPubMedGoogle Scholar
  34. Yoshida S, Yamashita S, Niwa T, Mori A, Ito S, Ichinose M, Ushijima T (2016) Epigenetic inactivation of FAT4 contributes to gastric field cancerization. Gastric cancer. doi: 10.1007/s10120-016-0593-5 PubMedCentralGoogle Scholar
  35. Zhang D, Fan D (2010) New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol 6:527–537CrossRefPubMedGoogle Scholar
  36. Zhao B, Li L, Lei Q, Guan KL (2010) The hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 24:862–874CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The International CCN Society 2016

Authors and Affiliations

  • Maryam Pilehchian Langroudi
    • 1
    • 2
  • Novin Nikbakhsh
    • 3
  • Ali Akbar Samadani
    • 2
  • Sadegh Fattahi
    • 2
  • Hassan Taheri
    • 4
  • Shahryar Shafaei
    • 5
  • Galia Amirbozorgi
    • 6
  • Reza Pilehchian Langroudi
    • 7
  • Haleh Akhavan-Niaki
    • 1
    • 2
    Email author
  1. 1.Cellular and Molecular Biology Research CenterBabol University of Medical SciencesBabolIran
  2. 2.Department of Genetics, Faculty of MedicineBabol University of Medical SciencesBabolIran
  3. 3.Department of Surgery, Rouhani hospitalBabol University of Medical SciencesBabolIran
  4. 4.Department of Internal Medicine, Rouhani hospitalBabol University of Medical SciencesBabolIran
  5. 5.Department of Pathology, Rouhani hospitalBabol University of Medical SciencesBabolIran
  6. 6.North Research Center of Pasteur InstituteAmolIran
  7. 7.Department of Anaerobic Vaccine Research and ProductionRazi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO)KarajIran

Personalised recommendations